JP2006528643A5 - - Google Patents

Download PDF

Info

Publication number
JP2006528643A5
JP2006528643A5 JP2006521295A JP2006521295A JP2006528643A5 JP 2006528643 A5 JP2006528643 A5 JP 2006528643A5 JP 2006521295 A JP2006521295 A JP 2006521295A JP 2006521295 A JP2006521295 A JP 2006521295A JP 2006528643 A5 JP2006528643 A5 JP 2006528643A5
Authority
JP
Japan
Prior art keywords
halo
membered
alkyl
alkenyl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006521295A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006528643A (ja
JP4521777B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/023914 external-priority patent/WO2005009988A1/en
Publication of JP2006528643A publication Critical patent/JP2006528643A/ja
Publication of JP2006528643A5 publication Critical patent/JP2006528643A5/ja
Application granted granted Critical
Publication of JP4521777B2 publication Critical patent/JP4521777B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006521295A 2003-07-24 2004-07-23 疼痛治療または予防に有用な４−ヘテロアリール−テトラヒドロピペリジル化合物 Expired - Fee Related JP4521777B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48951603P 2003-07-24 2003-07-24
PCT/US2004/023914 WO2005009988A1 (en) 2003-07-24 2004-07-23 Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain

Publications (3)

Publication Number Publication Date
JP2006528643A JP2006528643A (ja) 2006-12-21
JP2006528643A5 true JP2006528643A5 (enExample) 2008-03-06
JP4521777B2 JP4521777B2 (ja) 2010-08-11

Family

ID=34102893

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006521295A Expired - Fee Related JP4521777B2 (ja) 2003-07-24 2004-07-23 疼痛治療または予防に有用な４−ヘテロアリール−テトラヒドロピペリジル化合物

Country Status (28)

Country Link
US (4) US7776861B2 (enExample)
EP (2) EP1648879B1 (enExample)
JP (1) JP4521777B2 (enExample)
KR (2) KR20080092473A (enExample)
CN (3) CN102442995A (enExample)
AT (2) ATE431822T1 (enExample)
AU (1) AU2004259358B2 (enExample)
BR (1) BRPI0412248B1 (enExample)
CA (1) CA2533515C (enExample)
CY (1) CY1109318T1 (enExample)
DE (2) DE602004021206D1 (enExample)
DK (2) DK1867644T3 (enExample)
EA (1) EA009480B1 (enExample)
EG (1) EG25185A (enExample)
ES (1) ES2327684T3 (enExample)
GE (1) GEP20094675B (enExample)
HR (1) HRP20090442T1 (enExample)
IL (2) IL173344A (enExample)
IS (1) IS2593B (enExample)
MA (1) MA27948A1 (enExample)
MX (1) MXPA06000940A (enExample)
NO (1) NO331675B1 (enExample)
NZ (1) NZ544009A (enExample)
PT (1) PT1867644E (enExample)
SI (1) SI1867644T1 (enExample)
UA (1) UA83855C2 (enExample)
WO (1) WO2005009988A1 (enExample)
ZA (1) ZA200509997B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100777169B1 (ko) 2001-01-29 2007-11-16 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서함유하는 의약 제제
US7157462B2 (en) * 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
AR044688A1 (es) * 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
DE602004021206D1 (de) * 2003-07-24 2009-07-02 Euro Celtique Sa Zur Behandlung oder Vorbeugung von Schmerzen geeignete Heteroaryl-Tetrahydropiperidyl-Verbindungen
PL1867644T3 (pl) 2003-07-24 2009-10-30 Euro Celtique Sa Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
US8315162B2 (en) 2006-08-24 2012-11-20 Research In Motion Limited System and method for determining that a maximum number of IP sessions have been established
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
CA2685266C (en) 2007-04-27 2014-01-28 Purdue Pharma L.P. Trpv1 antagonists and uses thereof for the treatment of prevention of pain, ui and ulcer, ibd, or ibs in an animal
JP5372913B2 (ja) * 2007-04-27 2013-12-18 パーデュー、ファーマ、リミテッド、パートナーシップ 疼痛治療に有効な治療薬
AU2011226773C1 (en) * 2007-04-27 2012-07-26 Purdue Pharma L.P. TRPV1 antagonists and uses thereof
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
US8703962B2 (en) * 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
WO2011162409A1 (en) * 2010-06-22 2011-12-29 Shionogi & Co., Ltd. Compounds having trpv1 antagonistic activity and uses thereof
TW201211029A (en) * 2010-08-20 2012-03-16 Gruenenthal Gmbh Substituted cyclic carboxamide and urea derivatives as ligands of the vanilloid receptor
AR084457A1 (es) 2010-12-22 2013-05-15 Lundbeck & Co As H Derivados de biciclo[3,2,1]octilamida
US9156830B2 (en) 2011-05-17 2015-10-13 Shionogi & Co., Ltd. Heterocyclic compounds
PE20141531A1 (es) 2011-06-22 2014-10-23 Purdue Pharma Lp Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos
WO2013021276A1 (en) 2011-08-10 2013-02-14 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
US8924211B2 (en) * 2012-07-09 2014-12-30 Nuance Communications, Inc. Detecting potential significant errors in speech recognition results
US9064492B2 (en) 2012-07-09 2015-06-23 Nuance Communications, Inc. Detecting potential significant errors in speech recognition results
WO2015044759A1 (en) 2013-09-24 2015-04-02 Purdue Pharma L.P. Treatment of burn pain by trpv1 modulators
WO2015148271A1 (en) * 2014-03-26 2015-10-01 Vivid Pharma, Inc. Compositions for treating or preventing alcohol-induced symptoms
US10668041B2 (en) 2014-12-08 2020-06-02 Societe Des Produits Nestle Sa Compositions and methods comprising medium chain triglycerides for treatment of epilepsy
WO2016092459A1 (en) * 2014-12-08 2016-06-16 Nestec Sa Compositions and methods comprising medium chain triglycerides for treatment of epilepsy
RS62639B1 (sr) 2015-07-06 2021-12-31 Alkermes Inc Hetero-halo inhibitori histonskih deacetilaza
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
WO2017202376A1 (zh) * 2016-05-26 2017-11-30 南京明德新药研发股份有限公司 磺酰胺衍生物
IL322013A (en) 2016-07-29 2025-09-01 Janssen Pharmaceutica Nv Niraparib or its salts for use in the treatment of prostate cancer
JP6756925B2 (ja) 2017-01-11 2020-09-16 ロダン・セラピューティクス，インコーポレーテッド ヒストンデアセチラーゼの二環式阻害剤
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
GB201709459D0 (en) * 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
ES2914355T3 (es) 2017-08-07 2022-06-09 Alkermes Inc Inhibidores bicíclicos de la histona desacetilasa
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen
EP4613272A1 (en) 2022-10-31 2025-09-10 Shionogi & Co., Ltd Use of pyridine derivative which is trpv1 antagonist

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
BE757436A (fr) * 1969-10-27 1971-03-16 Robins Co Inc A H 1-carbamoyl-4-phenyl-piperidines et -tetrahydropyridines, leur procede de preparation et leurs applications comme anticonvulsivants et relaxants musculaires
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
DE3440141A1 (de) 1984-11-02 1986-05-07 Heiner Dipl.-Chem. Dr. 8000 München Eckert Verwendung von kohlensaeure-bis-trichlormethylester als proreagens fuer phosgen
JPH0680054B2 (ja) 1985-06-19 1994-10-12 吉富製薬株式会社 ピペリジン誘導体
US5316759A (en) 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US4797419A (en) * 1986-11-03 1989-01-10 Warner-Lambert Company Method of treating the symptoms of senile cognitive decline employing di- or trisubstituted urea cholinergic agents
DE3822792C2 (de) 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
US5198459A (en) 1987-07-11 1993-03-30 Sandoz Ltd. Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
US5506191A (en) 1987-11-02 1996-04-09 Sandoz Ltd. Heterocyclic hydrazines and hydrazones
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US6204284B1 (en) 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5232934A (en) 1992-07-17 1993-08-03 Warner-Lambert Co. Method for the treatment of psychomotor stimulant addiction
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5556837A (en) 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
US5762925A (en) 1994-11-03 1998-06-09 Sagen; Jacqueline Preventing opiate tolerance by cellular implantation
AU6111796A (en) 1995-06-12 1997-01-09 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5 -lipoxygenase inhibitor
KR100384979B1 (ko) 1995-09-07 2003-10-17 에프. 호프만-라 로슈 아게 심부전증및신부전증치료용의신규한4-(옥시알콕시페닐)-3-옥시-피페리딘
FR2740134B1 (fr) 1995-10-18 1998-01-09 Pf Medicament Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant
FR2744448B1 (fr) * 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
DE69720038T2 (de) 1996-12-13 2003-08-28 Banyu Pharmaceutical Co., Ltd. Aminopyrazolderivate
FR2758328B1 (fr) * 1997-01-15 1999-04-02 Pf Medicament Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
DE69819345T2 (de) 1997-08-20 2004-07-15 The Regents Of The University Of California, Oakland Für den capsaicin rezeptor kodierende nukleinsäuresequenzen und dem capsaicin rezeptor ähnliche polypeptide und ihre verwendung
EP0943683A1 (en) 1998-03-10 1999-09-22 Smithkline Beecham Plc Human vanilloid receptor homologue Vanilrep1
WO1999065896A1 (en) 1998-06-19 1999-12-23 Eli Lilly And Company Preparation of heteroaryl compounds
ES2151828B1 (es) 1998-07-10 2001-08-16 Esteve Labor Dr Empleo de derivados de tetrahidropiridinas (ohidroxi-piperidinas)-b utilazoles en la elaboracion de un medicamento para el tratamiento del dolor.
BR9914018A (pt) 1998-09-22 2001-07-03 Yamanouchi Pharmaceuticals Co Derivado de cianofenila
SE9803773D0 (sv) 1998-11-05 1998-11-05 Astra Pharma Prod Compounds
DE69907963T2 (de) 1998-12-23 2004-05-19 Eli Lilly And Co., Indianapolis Heteroaromatische amide als inhibitoren von faktor xa
AU3215500A (en) 1999-01-25 2000-08-07 Smithkline Beecham Corporation Compounds and methods
GB9907097D0 (en) 1999-03-26 1999-05-19 Novartis Ag Organic compounds
AU4797400A (en) * 1999-05-17 2000-12-05 Eli Lilly And Company Metabotropic glutamate receptor antagonists
AU7514700A (en) * 1999-09-07 2001-04-10 Syngenta Participations Ag Cyanopiperidines
US20030087917A1 (en) 2000-03-27 2003-05-08 Dorothea Strack Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system
US6930185B2 (en) 2000-04-28 2005-08-16 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
KR100858642B1 (ko) 2000-05-22 2008-09-17 아벤티스 파마슈티칼스 인크. 트립타제 억제제로서 사용하기 위한 아릴메틸아민 유도체
BR0112395A (pt) 2000-06-21 2003-07-08 Hoffmann La Roche Derivados de benzotiazol
WO2002005819A1 (en) 2000-07-15 2002-01-24 Smithkline Beecham Corporation Compounds and methods
KR20030024799A (ko) 2000-07-20 2003-03-26 뉴로젠 코포레이션 캡사이신 수용체 리간드
EP1437344A4 (en) 2001-09-28 2006-09-20 Takeda Pharmaceutical BENZENE DERIVATIVES AND PROCESS FOR THE PREPARATION AND USE THEREOF
JP2005516950A (ja) * 2001-12-19 2005-06-09 メルク　エンド　カムパニー　インコーポレーテッド 代謝型グルタミン酸受容体−５のヘテロアリール置換イミダゾールモジュレータ
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
ATE465993T1 (de) 2002-02-01 2010-05-15 Euro Celtique Sa 2-piperazinpyridine für die schmerzbehandlung
JP2005526723A (ja) 2002-02-15 2005-09-08 グラクソ　グループ　リミテッド バニロイド受容体モジュレーター
US6974818B2 (en) * 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US20030232836A1 (en) 2002-05-23 2003-12-18 Stewart Andrew O. Acetamides and benzamides that are useful in treating sexual dysfunction
WO2003099266A2 (en) 2002-05-23 2003-12-04 Abbott Laboratories Acetamides and benzamides that are useful in treating sexual dysfunction
AU2003248245A1 (en) 2002-06-26 2004-01-19 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
BR0312322A (pt) 2002-06-28 2005-04-12 Euro Celtique Sa Compostos, composições, métodos para o tratamento da dor em um animal, da incontinência urinária em um animal, de uma úlcera em um animal, de sìndrome de intestino irritável em um animal, da doença inflamatória do intestino em um animal, métodos para a inibição da função de vr1 em uma célula, kits e métodos para a preparação de uma composição
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
DE10252666A1 (de) 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7067509B2 (en) 2003-03-07 2006-06-27 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
DE10311065A1 (de) 2003-03-13 2004-09-23 Abbott Gmbh & Co. Kg Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
AU2004234040A1 (en) 2003-04-28 2004-11-11 Actelion Pharmaceuticals Ltd Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors
ATE556067T1 (de) 2003-05-20 2012-05-15 Ajinomoto Kk Modulatoren des vanilloid rezeptors
AR044688A1 (es) 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
US20050009841A1 (en) 2003-07-11 2005-01-13 Zheng Guo Zhu Novel amides useful for treating pain
US7129235B2 (en) 2003-07-11 2006-10-31 Abbott Laboratories Amides useful for treating pain
DE602004021206D1 (de) 2003-07-24 2009-07-02 Euro Celtique Sa Zur Behandlung oder Vorbeugung von Schmerzen geeignete Heteroaryl-Tetrahydropiperidyl-Verbindungen
DE602004020994D1 (de) 2003-07-24 2009-06-18 Euro Celtique Sa Piperidinverbindungen und pharmazeutische zusammensetzungen, die diese enthalten
CA2533898A1 (en) 2003-07-29 2005-02-10 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
JP4831577B2 (ja) 2003-07-30 2011-12-07 ゼノン・ファーマシューティカルズ・インコーポレイテッド ピリダジン誘導体および治療剤としての用途
EP1651620B1 (en) 2003-07-30 2011-11-09 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
SI1648880T1 (sl) 2003-08-01 2010-05-31 Euro Celtique Sa Terapevtska sredstva uporabna za zdravljenje bolečine
DE602004031163D1 (de) 2003-09-22 2011-03-03 Euro Celtique Sa Phenylcarboxamidverbindungen zur Schmerzbehandlung
US20050130974A1 (en) 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
AU2004293026B2 (en) 2003-11-21 2012-01-19 Array Biopharma Inc. AKT protein kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2006528643A5 (enExample)
JP2007504284A5 (enExample)
JP2009526868A5 (enExample)
JP2004182741A5 (enExample)
JP2005523922A5 (enExample)
RU2014107430A (ru) Моногидрат мезилата n-[5-(аминосульфонил)-4-метил-1,3-тиазол-2-ил]-n-метил-2-[4-(2-пиридинил)фенил]ацетамида
JP2004521124A5 (enExample)
JP2013504593A5 (enExample)
JP2004517813A5 (enExample)
JP2006514114A5 (enExample)
JP2008504265A5 (enExample)
JP2009508811A5 (enExample)
JP2008511601A5 (enExample)
JP2010090149A5 (enExample)
JP2005526836A5 (enExample)
JP2014515349A5 (enExample)
JP2005535731A5 (enExample)
JP2007502817A5 (enExample)
JP2005525392A5 (enExample)
JP2006504738A5 (enExample)
JP2003012668A5 (enExample)
JP2007039449A5 (enExample)
JP2007532627A5 (enExample)
JPWO2021049504A5 (enExample)
JP2013544854A5 (enExample)